What is JBIO's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.92B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for JBIO?

P/E (TTM) is n/a and 52-week range is $8.36 to $28.00 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s JBIO figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for JBIO?

The company profile lists net income (TTM) near $-173M, EPS (TTM) near $-2.84 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Jade Biosciences Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Waltham, Massachusetts, US, 60.9M shares outstanding, ISIN US0080642061 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Jade Biosciences Inc

$JBIO

Health Care · Biotechnology

IR Run Scenarios

$14.39

+1.70%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Jade Biosciences, Inc. is a biotechnology company which engages in the development of drugs for rare cardiopulmonary disease. The company is headquartered in Waltham, Massachusetts and currently employs 55 full-time employees. The company went IPO on 2021-06-30. The Company’s lead asset, JADE-001, is an investigational anti-A PRoliferation-Inducing Ligand (APRIL) monoclonal antibody for the treatment of Immunoglobulin A (IgA) nephropathy (IgAN), an autoimmune condition in which the kidney is damaged by pathogenic IgA containing immune complexes, leading to proteinuria and kidney function decline, and potentially progressing to end-stage kidney disease requiring dialysis or transplantation. Designed to block the APRIL protein, JADE-001 targets an underlying cause of IgAN, offering the potential to reduce pathogenic IgA levels, decrease proteinuria, and preserve kidney function over the long term. The Company’s pipeline also includes two undisclosed antibody discovery programs: JADE-002 and JADE-003, which are in preclinical development.

Employees

Website

jadebiosciences.com/

IPO

2021-06-30

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)